8 results
IgM and Non-IgM - Risk and Type of Progression #EBM #Honc #MGUS #Progression #IgM #NonIgM #MultipleMyeloma
IgM and Non-IgM ... Progression #EBM #Honc ... #MGUS #Progression ... #IgM #NonIgM #MultipleMyeloma ... #NEJM
Cumulative Incidence of Progression of MGUS, with Death Accounted for as a Competing Risk #EBM #Honc
Progression of MGUS ... Competing Risk #EBM #Honc ... #MGUS #Progression ... #IgG #MGUS #NEJM
Paraproteinemias

Entities That Can Feature A Monoclonal Protein/M Component:
• MM
• WM
• MGUS
• MGCS
• MGRS
• Splenic Marginal Zone
• MM • WM • MGUS ... • MGCS • MGRS ... Scleromyxedema (Dermato-neuro ... Hypergammaglobulinemic macular ... anticoagulant • IgM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
End Points #EBM #Neuro ... #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #Results #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Adverse Events in the Safety Population, According
Trial Group #EBM #Neuro ... #IM #Fremanezumab ... AdverseEvents #NEJM ... #NEJM
Fremanezumab for the Preventive Treatment of Chronic Migraine - Primary and Secondary End Points #EBM #Neuro
End Points #EBM #Neuro ... #IM #Fremanezumab ... CalcitoninGeneRelatedPeptideAntibody #NEJM
Hemolysis in Hereditary Spherocytosis. Panel A shows the structure of a normal red cell and a
Pathophysiology #Honc ... #IM #Spherocytosis ... HereditarySpherocytosis #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
Pathophysiology #IM ... #Honc #Pharm #GVHD ... Immunosuppression #NEJM